Allergan health news articles

Allergan's BOTOX will be available in European Countries for Urinary Incontinence
Allergan is pleased to announce that BOTOX (botulinum toxin type A) has received a positive opinion from the Irish Medicines Board for the management of urinary incontinence in adults with neurogenic detrusor overactivity (NDO) resulting from neurogenic bladder due to stable sub-cervical spinal cord injury, or multiple sclerosis.

Allergan agreed to pay $600 million to US Government
Allergan, Inc. (NYSE: AGN) announced that it has reached a resolution with the United States Department of Justice (DOJ) regarding the previously reported Government investigation into Allergan's past U.S. sales and marketing practices relating to certain therapeutic uses of BOTOX(R) (onabotulinumtoxinA).

Latisse approved for hypotrichosis of eyelashes
Allergan, Inc. (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has approved LATISSE(TM) (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.

Allergan confirms fatality not caused by Botox cosmetic
In response to public reports suggesting a causal link between a BOTOX(R) Cosmetic treatment in 2003 and a fatality, Allergan, Inc. (NYSE:AGN) provided further assurance to patients and the public about BOTOX(R) Cosmetic and BOTOX(R) (Botulinum Toxin Type A).

Health news organizations - A

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
1.77